Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Harpoon Therapeutics Inc
NASDAQ HARP
Data sourced from
and
and
Harpoon Therapeutics Inc Return on Assets (ROA) 5 year CAGR for the quarter ending September 30, 2023: -28.95%
Harpoon Therapeutics Inc Return on Assets (ROA) 5 year CAGR is -28.95% for the quarter ending September 30, 2023. Return on assets (ROA) measures the profitability of a company relative to its total assets. It is calculated by dividing the net income by the total assets. This ratio indicates how effectively a company utilizes its assets to generate profits. A higher ROA suggests a more efficient use of assets and indicates better profitability. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
-
Harpoon Therapeutics Inc Return on Assets (ROA) for the quarter ending September 30, 2022 was -13.64%, a -42.84% change year over year.
-
Harpoon Therapeutics Inc Return on Assets (ROA) for the quarter ending September 30, 2021 was -9.55%, a -31.57% change year over year.
-
Harpoon Therapeutics Inc Return on Assets (ROA) for the quarter ending September 30, 2020 was -7.26%, a 35.03% change year over year.
-
Harpoon Therapeutics Inc Return on Assets (ROA) for the quarter ending September 30, 2019 was -11.17%, a 46.60% change year over year.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: HARP
| CEO | Ms. Julie M. Eastland M.B.A. |
| IPO Date | Feb. 8, 2019 |
| Location | United States |
| Headquarters | 131 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 |
| Employees | 53 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California. As of March 11, 2024, Harpoon Therapeutics, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.
Key trends
Similar companies
Stoke Therapeutics Inc
NA
NA
StockViz Staff
September 20, 2024
Any question? Send us an email